ArticleNAM journal2026
From vivarium to NAM-centred laboratory: A practical framework for managing infrastructure, expertise and organisational transition.
Article in NAM journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Political, Regulatory and Scientific developments are propelling the use of New Approach Methodologies (NAMs) across regulatory toxicology and drug development, creating challenges for organisations operating animal-testing facilities. High clinical attrition rates driven by lack of efficacy and toxicity continue to stimulate interest in more human-predictive approaches. The FDA Modernization Acts and UK and EU initiatives to phase out animal testing are also influencing future testing strategies. Universities, pharmaceutical companies and contract research organisations (CROs) have made substantial investments in facilities, equipment, support services and highly skilled personnel. Increasing adoption of NAMs forces existing infrastructure redevelopment, whilst preserving capital investment and retaining/repurposing scientific expertise. A practical framework is presented for organisations transitioning from animal-based testing towards NAM-centred operations, addressing infrastructure redevelopment, workforce transition, expertise retention and capital investment preservation. Infrastructure requirements, support services, workforce development, business sustainability and role-specific staff retraining are examined. Retaining institutional knowledge and recognising the continuing value of technical, scientific and regulatory expertise developed through animal-testing programmes as organisations transition towards NAMs are prioritised. Contexts of Use (CoUs) and Adverse Outcome Pathways (AOPs) help connect historical animal-study knowledge with future NAM applications. Successful transition is presented as a managed organisational process involving people, infrastructure, knowledge and investment rather than simply the replacement of one experimental model with another.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.